#Paris #France #Eligo Bioscience #Genetic Medicine #Immunodermatology

Eligo Bioscience Receives $5 Million for Genetic Medicine Advancement

Eligo Bioscience, a trailblazer in genetic medicine, has secured a significant grant of $5 million from the French government, aimed at advancing its innovative platform designed for treating skin conditions through genetic interventions. This funding aligns with the initiative “Innovations in Biotherapies and Bioproduction,” orchestrated by the Health Innovation Agency as part of the France 2030 strategy, and is managed by Bpifrance on behalf of the French government.

This financial boost comes at a crucial time for Eligo as the company aims to enhance its proprietary genetic topical administration platform, enabling local biological therapeutic production via skin-resident bacteria. This novel approach promises to provide new avenues for treatment methodologies focused on the intricacies of human skin microbiome and immune regulation.

Key Achievements and Developments

Eligo's recent achievements further complement this grant. The company published its microbiome editing platform in the prestigious journal Nature and has garnered multiple pivotal patents involving skin microbiome editing. Their Series B funding round recently expanded to an impressive $35 million, marking a strong financial foundation to support their clinical product development pipeline.

Dr. Xavier Duportet, CEO and co-founder of Eligo Bioscience, stated, “This funding allows us to establish a robust bioproduction process for our groundbreaking gene-editing topical therapies aimed at the microbiome, setting the groundwork for our expansion into a wide range of immunodermatological indications.” He expressed ambition for the company to provide genuinely transformative therapeutic solutions that address critical medical challenges faced by millions worldwide.

Clinical Advancement Plans

With the support from this grant, Eligo plans to optimize and scale the bioproduction of its first-generation topical therapy using CRISPR technology, targeted specifically at treating moderate to severe acne. To facilitate this, Eligo has partnered with Biose Industries, a globally recognized Contract Development and Manufacturing Organization (CDMO) that specializes in microbial fermentation. Biose's extensive expertise in Good Manufacturing Practice (GMP) regarding complex microbial therapies will be instrumental in accelerating Eligo’s progress towards clinical validation.

Focus on Immunodermatology

The human skin microbiome plays a critical role in skin immune regulation, harboring commensal bacteria near immune cells within hair follicles. Eligo’s unique in-situ delivery modality enables the genetic engineering of these bacteria, transforming them into localized bioreactors capable of expressing high-potency biological products precisely where immune dysregulation occurs. The new funding will support the exploration of various therapeutic payloads, aiming to establish a broad portfolio targeting chronic inflammatory skin diseases and immune-mediated conditions that currently lack effective treatments.

Eligo Bioscience’s innovative efforts are expected to pave the way for substantial advancements in the medical field, particularly for patients suffering from debilitating skin disorders. The company is dedicated to leveraging this grant to bolster its research and development, with aspirations to deliver cutting-edge genetic therapies that make a meaningful difference in patient health and well-being.

For additional information about Eligo Bioscience and its role in advancing genetic medicine under the France 2030 initiative, visit their website.